International Trade Bulletin - Volume 1, Issue 10
Client Alert | 2 min read | 07.24.06
Inside this issue:
- ANTI-DUMPING IN THE SPOTLIGHT
- Comparison of The EU and U.S. Anti-Dumping Models: A Common Question Asked, Especially by Multilateral Companies, is “What are the Key Differences Between the U.S. and EU Systems for Imposing Anti-Dumping Duties?”
- EU Anti-Dumping: Spreading the Costs and Impact of Imposing EU Anti-Dumping Measures
- U.S. Anti-Dumping: More Trouble for the “Byrd Act” at Home
- THE WTO IN THE SPOTLIGHT
- WTO D-G Pascal Lamy Makes Plea to G-8 to Save The DDA: The Director-General of the WTO, Pascal Lamy, has warned leaders at the G-8 meeting in St. Petersburg, Russia, that the DDA multilateral round will fail without their intervention
- Review System Adopted For Approving Regional Trade Agreements: The WTO's Negotiating Group on Rules has given formal approval of a new transparency mechanism for assessing all future regional trade agreements (RTAs) and their compatibility with the WTO rules
- Vietnam Set to Become 150th Member of The WTO: The chairperson of Vietnam's membership negotiations announces final agreement on accession to be put before the WTO General Council meeting in October
- RUSSIA: Russia Within Striking Distance of Joining the World Trade Organization as the U.S. and Russia Gets Close to Reaching a Deal on Russia's Accession
- SANCTIONS: The State Department has rescinded the 1979 designation of Libya as a state sponsor of terrorism in a notice published in the Federal Register on July 13, 2006
- MARKET ACCESS: U.S. and Cambodia Sign Trade and Investment Framework Agreement
- JAPAN: The U.S. and Japan Release Deregulation Report Highlighting New Opportunities for U.S. Industry
- AVIATION: Airlines Studying Proposed New U.S. Rule Mandating Pre-Departure Submission of Passenger Data
- BILATERAL TRADE: Signaling a growing frustration with the multilateral trade negotiation processes, currently moving at a snail's pace under the increasingly inappropriately named “Doha Development Round”, the EU begins putting in place the building blocks for a new wave of bilateral trade agreements
Contacts
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
